Remepy is harnessing the power of our digital world to improve drugs. We combine medicine with tailored software applications, triggering brain mechanisms that positively influence our immune system, increasing drug efficacy and safety. We offer our platform to pharma companies, enabling them to launch patentable software-drug combinations.
Founded date: 2022
Investors 3
| Date | Name | Website |
| - | TechAviv F... | techaviv.c... |
| 29.11.2022 | TechAviv F... | fund.techa... |
| 27.01.2023 | Supernode ... | supernode.... |
Mentions in press and media 2
| Date | Title | Description |
| 01.05.2024 | Remepy Closes $15M Seed Funding | Remepy, a New York-based hybrid drugs developer, closed a $10M seed funding round, which, together with earlier funding, totalled $15M. The round was led by NFX, joined by Vine Ventures, PsyMed Ventures, Supernode Ventures and Firstime Vent... |
| 14.02.2024 | Naftali Bennett and Michal Tsur unite at Remepy: Former PM joins Board for hybrid drug endeavor | This is the third high-tech board Bennett has joined since he left politics, previously joining AI cyber company Lasoo and quantum computing startup Quantum Source. Tsur and Bennett founded Cyota in 1999 together with Ben Enosh and Lior Gol... |